Year in Review

Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology: 2010-2011

Select Publications

**Breast Cancer**


Chang JCN et al. TBCRC 006 — A multicenter Phase II study of neoadjuvant lapatinib and trastuzumab in HER2-overexpressing breast cancer (BC). *Proc ASCO* 2011;Abstract 505.


Holmes FA et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib or trastuzumab, alone or in combination, prior to neoadjuvant chemotherapy. *Proc ASCO* 2011;Abstract 506.


Yardley DA et al. Phase II study evaluating lapatinib in combination with nab®-paclitaxel in women who have received ≤1 chemotherapy regimen for HER2-overexpressing metastatic breast cancer. *San Antonio Breast Cancer Symposium* 2011;Abstract P1-12-10.

**Non-Small Cell Lung Cancer**


Fukuoka M et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). *Proc ASCO* 2009;Abstract 8006.

Miller V et al. Phase IIb/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Proc ESMO 2010;Abstract LBA1.


Rosell R et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. Proc ASCO 2011;Abstract 7503.


Spigel DR et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Proc ASCO 2011;Abstract 7505.

**Genitourinary Cancers**


Efstathiou MA et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. Proc ASCO 2011;Abstract 4501.


Hussain M et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a Phase II randomized discontinuation trial. Proc ASCO 2011;Abstract 4516.

Melichar B et al. BEVLiN — Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc ASCO 2011;Abstract 4546.


**Non-Hodgkin and Hodgkin Lymphomas**


Coiffier B et al. Final results from a pivotal, multicenter, international, open-label, Phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Proc ASH 2010;Abstract 114.
Fowler N et al. High response rates with lenalidomide plus rituximab for untreated, indolent, B cell NHL. *Proc ICML* 2011;Abstract 137.


Trotman J et al. FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent indicator of outcome for patients with follicular lymphoma: An analysis from the PRIMA study. *Proc ASH* 2010;Abstract 855.

**Multiple Myeloma**


Morgan G et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. *Proc ASCO* 2010;Abstract 8021.


Richardson PG et al. A Phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. *Proc ASH* 2010;Abstract 864.


**Gastrointestinal Cancers**


Kerr D et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. *Proc ASCO* 2009;Abstract 4000.


**Ovarian Cancer**

Aghajanian C et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). *Proc ASCO* 2011;Abstract LBA5007.


Kristensen G et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. *Proc ASCO* 2011;Abstract LBA5006.


